▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Cheryl Swanson

CherylSwanson

Cheryl has six books published, and currently resides in Hawaii with her husband, her daughter and two dozen surfboards. With a 20-year background as a former medical technology and management consultant, as well as a cancer survivor, Cheryl has a unique perspective on health care. Follow her on Twitter at @uthorcdswanson

Recent Articles by Cheryl Swanson

0000getty

Jul 18, 2016 by Cheryl Swanson, Cory Renauer, and Brian Feroldi

This Could Be the Next Big Pharma Buyout

Once biotech M&A heats up again, Acadia, Bluebird, and Jazz could be the first targets on the list, according to our Motley Fool contributors.

000cancerresearchUK

Jul 17, 2016 by Cheryl Swanson

Forget the Me-Too Cancer Drugs -- These Breakthroughs Are Where You Want to Invest

The FDA's oncology chief has wise advice for drugmakers -- and healthcare investors.

0000000commonflickr

Jun 13, 2016 by Cheryl Swanson

Tricking the Common Cold Into Destroying Cancer

Conquering cancer is set to go "viral", paving the way for a new generation of cancer treatments.

0000000bezosgates

May 29, 2016 by Cheryl Swanson

Are Jeff Bezos and Bill Gates Wrong About Illumina?

The tech titans are behind a test that could be the turning point in the war against cancer. But will it work?

May 24, 2016 by Cheryl Swanson, Cory Renauer, and Brian Feroldi

3 Stocks With Better Dividends Than Johnson & Johnson

Motley Fool contributors place their bets on what dividend payers could pay off better than JNJ long-term.

pipeline1Capture

Apr 12, 2016 by Cheryl Swanson, Keith Speights, and Cory Renauer

3 Nominations for Big Pharma's Riskiest Pipeline -- and Why They Qualify

Understanding the level of risk in a therapeutic pipeline leads to smarter investing. Our contributors tip you off on where to be wary, and what benchmarks to look for.

000000000questionmark

Apr 7, 2016 by Cheryl Swanson, Sean Williams, and Brian Feroldi

Where Will Valeant Pharmaceuticals International, Inc. Be in 10 years?

Our contributors weigh in on what could be ahead for the beleaguered drug company,

Genentech

Mar 19, 2016 by Cheryl Swanson

You'll Never Guess Which Pharma Likely Owns 40% of 2016's New Blockbusters

Roche/Genentech's late-stage pipeline is bubbling with blockbusters headed for make-or-break FDA decisions. Incredibly, the biggest new drug of all isn't even in cancer.

biotech1

Mar 18, 2016 by Cheryl Swanson, Kristine Harjes, and Brian Feroldi

3 Biotech Stocks to Buy in March

Our contributors identify biotechs that could be about to unfreeze and head higher.

foreverCapture

Mar 8, 2016 by Cheryl Swanson, Todd Campbell, and Brian Feroldi

3 Stocks to Hold Forever

These leading healthcare companies should be winners for years and years to come.

Feb 15, 2016 by Cheryl Swanson, Selena Maranjian, and Brian Feroldi

3 Biotechs that Could Snap Back and Soar Even Higher

Buying biotechs may seem like jumping without a net these days, but our contributors pinpoint three stocks packing plenty of snap back potential.

biotech

Feb 13, 2016 by Cheryl Swanson, Sean Williams, and Brian Feroldi

3 Upcoming FDA Decisions We're Most Excited About

Here's how Acadia, Intercept, and Clovis Oncology could win big in 2016.

obamahippiese

Jan 30, 2016 by Cheryl Swanson, Sean Williams, and Todd Campbell

Will Obamacare Fail in 2016? Here are 3 Stocks Set to Benefit if it Does

UnitedHealth, Aon, and Medtronic could take off if the ACA is rolled back.

Jan 28, 2016 by Cheryl Swanson, Selena Maranjian, and Sean Williams

Top Biotechs for 2016

Motley Fool contributors target three biotechs that could energize your portfolio in 2016.

dubre

Jan 19, 2016 by Cheryl Swanson, Keith Speights, and Todd Campbell

Where Could Pfizer Be in 10 Years?

Our contributors duke it out over the future of the world's largest drugmaker. See if you agree.

obamcarepixabay

Jan 12, 2016 by Cheryl Swanson, Selena Maranjian, and Keith Speights

Top Obamacare Stocks to Buy in 2016

Even as the GOP votes to repeal Obamacare for the 62nd time, these three stocks look primed for further gains.

neverheardof

Dec 19, 2015 by Cheryl Swanson, Sean Williams, and Keith Speights

3 Great Biotech Stocks You Haven't Heard Of

Never heard of these stocks? Here's why our contributors think that may change soon.

courtesywikiepedia

Dec 2, 2015 by Cheryl Swanson, Sean Williams, and Brian Stoffel

Where Will Organovo Holdings Be in 10 Years?

Predicting the future is a risky business, and as you'll see, our contributors don't always agree.

surprisedcatCapture

Nov 21, 2015 by Cheryl Swanson, Sean Williams, and Dan Caplinger

3 Earnings Reports That Surprised Us This Quarter

Visa, MannKind, and WOOF top the list of surprises for these Motley Fool contributors.

Corporatejet

Nov 9, 2015 by Cheryl Swanson, Selena Maranjian, and Sean Williams

America's 3 Most Overpaid CEOs

While these three CEOs are making out like bandits, are investors getting fleeced?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services